Pharmacological manipulation of CB2Rs
Drug	Species	Paradigm	Treatment, dose	Response	References
ACUTE TREATMENT
GW405833 (CB2R agonist)	Rats, Sprague-Dawley	MB	10 and 30 mg/kg	–	Valenzano et al. (2005)
		Rotarod	100 mg/kg	↓ Anxiety-like responses and ataxia
JWH015 (CB2R agonist)	Mouse, C57BL/6	EPM	1–20 mg/kg	↓ Anxiety-like responses	Onaivi (2006)
	Mouse, C57BL/6	LD	1–20 mg/kg	↑ Anxiety-like responses	Onaivi et al. (2008b)
JWH133 (CB2R agonist)	Mouse, Swiss ICR	LD	0.5, 1, and 2 mg/kg	–	García-Gutiérrez et al. (2011)
SR144528 (CB2R antagonist)	Mouse, BALBc	LD	1–20 mg/kg	–	Onaivi et al. (2008b)
AM630 (CB2R antagonist)	Mouse, Swiss ICR	LD	1, 2, or 3 mg/kg	↑ Anxiety-like responses	García-Gutiérrez et al. (2011)
CHRONIC TREATMENT
JWH133 (CB2R agonist)	Mouse, Swiss ICR	LD	0.5, 1, or 2 mg/kg	↑ Anxiety-like responses	García-Gutiérrez et al. (2011)
		EPM	1 week (twice a day)
JWH015 (CB2R agonist)	Mouse, BALBc	AT	20 mg/kg	Enhanced sucrose consumption	Onaivi et al. (2008b)
			4 weeks (once a day)
AM630 (CB2R antagonist)	Mouse, BALBc	AT	1 and 3 mg/kg	–	Onaivi et al. (2008b)
			4 weeks (once a day)
	Mouse, Swiss ICR	CUMS	1, 2, and 3 mg/kg	Antidepressant-like	García-Gutiérrez et al. (2010)
			4 weeks (twice a day)
	Mouse, Swiss ICR	LD	1, 2, and 3 mg/kg	↓ Anxiety-like responses	García-Gutiérrez et al. (2011)
		EPM	1 week (twice a day)

All drugs were administered intraperitoneally (ip).Behavioral paradigms: OF, Open field; LD, light–dark box; EPM, elevated plus-maze; TST, tail suspension test; SDIA, step down inhibitory avoidance; PPI, pre-pulse inhibition of the acoustic startle response; NSFT, novelty-suppressed feeding test; CUMS: chronic unpredictable mild stress; MB, marble burying test; AT, anhedonia test: sucrose consumption. Symbols, ↑ increased (anxiogenic-like), ↓ decreased (anxiolytic-like), or – no changes in behaviour.